Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Phase 1 Clinical Study to Evaluate the Safety and Tolerability of Subcutaneous Elamipretide in Subjects With Intermediate Age-Related Macular Degeneration

Next Previous
Trial Profile

An Open-Label, Phase 1 Clinical Study to Evaluate the Safety and Tolerability of Subcutaneous Elamipretide in Subjects With Intermediate Age-Related Macular Degeneration

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 26 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Elamipretide (Primary)
  • Indications Dry age-related macular degeneration
  • Focus Therapeutic Use
  • Acronyms ReCLAIM
  • Sponsors Stealth BioTherapeutics

    • Most Recent Events

    • 11 Nov 2021 According to a Stealth BioTherapeutics media release, the Company presented data from trial at recent conferences, including EURETINA 2021 Virtual Congress, the Annual Scientific Session of The Retina Society, and the American Society of Retina Specialist (ASRS) Annual Scientific Meeting.
    • 14 Sep 2021 According to a Stealth BioTherapeutics media release, clinical findings from the study will be presented at several leading ophthalmic conferences this fall, including EURETINA 2021 Virtual Congress, Annual Scientific Session of The Retina Society 2021, American Society of Retina Specialist (ASRS) Annual Scientific Meeting 2021 and American Academy of Ophthalmology (AAO) 2021.
    • 18 May 2021 According to a Stealth BioTherapeutics media release, ReCLAIM Phase 1 data supports ReCLAIM-2 Phase 2 geographic atrophy trial design.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top